Photobiomodulation and visual stimulation against cognitive decline and Alzheimer's disease pathology: A systematic review

Abstract

Introduction Given the ineffectiveness of the available drug treatment against Alzheimer disease (AD), light‐based therapeutic modalities have been increasingly receiving attention with photobiomodulation (PBM) and, more recently, visual stimulation (VS) being among the most promising approaches. However, the PBM and VS light parameters tested so far, as well as their outcomes, vary a lot with conflicting results being reported. Methods Based on Scopus, PubMed, and Web of Science databases search, this systematic review summarizes, compares, and discusses 43 cell, animal, and human studies of PBM and VS related to cognitive decline and AD pathology. Results Preclinical work suggests that PBM with 640±30‐nm light and VS at 40 Hz attenuates Aβ and Tau pathology and improves neuronal and synaptic plasticity with most studies pointing towards enhancement of degradation/clearance mechanisms in the brain of AD animal models. Despite the gap of the translational evidence for both modalities, the few human studies performed so far support the use of PBM at 810‐870 nm light pulsing at 40 Hz for improving brain network connectivity and memory in older subjects and AD patients, while 40 Hz VS in humans seems to improve cognition; further clinical investigation is urgently required to clarify the beneficial impact of PBM and VS in AD patients. Discussion This review highlights PBM and VS as promising light‐based therapeutic approaches against AD brain neuropathology and related cognitive decline, clarifying the most effective light parameters for further preclinical and clinical testing and use. Highlights Light‐based brain stimulation produces neural entrainment and reverts neuronal damage Brain PBM and VS attenuate AD neuropathology PMB and VS are suggested to improve cognitive performance in AD patients and animal models Light stimulation represents a promising therapeutic strategy against neurodegeneration

Semiconducting Polymer Nanoporous Thin Films as a Tool to Regulate Intracellular ROS Balance in Endothelial Cells

“…The narrowing of the maximum absorption peak of P3HT 28 - g -PLA 72 porous thin films and blue shift to 420 nm could be attributed both to a decrease in interchain interaction and to an increase of the amorphous polymer phase, as proven by GIWAXS measurements (Figure S4), toward a rougher film surface as shown by AFM . These results demonstrate that both non-porous and porous thin films absorb light in the visible range, making them accurate for optoceutical therapies. , Then, the fluorescence emission properties of the thin films after excitation at 480 nm were studied. The fluorescence emission spectra of non-porous thin films show two main emission maximum peaks at 516 and 630 nm (Figure c).…”

Optimization of a Photobiomodulation Protocol to Improve the Cell Viability, Proliferation and Protein Expression in Osteoblasts and Periodontal Ligament Fibroblasts for Accelerated Orthodontic Treatment

“…PBM promotes cellular activity and consequently effects cell viability, proliferation and growth via the stimulation of the mitochondrial respiratory chain, resulting in enhanced mitochondrial membrane potential and increased ATP synthesis [3,4,8,11,20,27]. This ability to modulate cellular dynamics has been used in different areas of biomedicine for several years [1,28,29]. In orthodontics, its effectiveness in accelerating OTM is based on its ability to regulate bone remodeling mediators [1,[30][31][32][33].…”

Photobiomodulation in experimental models of Alzheimer’s disease: state-of-the-art and translational perspectives

“…This involves the non-invasive delivery of visible and/or NIR light, typically using light-emitting diodes (LED) applied to the head and brain regions for appropriate lengths of time (typically 10—30 min) [ 13 , 22 ]. The primary effects of transcranial PBM with various light parameters in cell, animal, and human studies have been systematically reviewed elsewhere [ 23 , 24 ]. These reviews highlight the potential of this therapy against neurodegeneration.…”